EZH2 and lymphoma: EZH2 gain-of-function mutations are not sufficient on their own for lymphoma development; however, they represent a driving hit in lymphoid transformation, in association with the deregulation of other genes, such as c-MYC or BCL2 [80, 81] (Figure 3).